外科理论与实践

外科理论与实践 >

2022 , Vol. 27 >Issue 05: 416 - 420

DOI: https://doi.org/10.16139/j.1007-9610.2022.05.008

指南与共识

ER+/HER2-乳腺癌多基因阵列检测应用：ASCO指南解读与瑞金医院临床实践

展开
  • 上海交通大学医学院附属瑞金医院外科 乳腺疾病诊治中心，上海 200025

收稿日期: 2022-08-15

  网络出版日期: 2022-11-10

收起

Multi-gene assay profiling testing in ER+/HER2- breast cancer: ASCO guidelinesinterpretation and Ruijin Hospital experience

Expand

Received date: 2022-08-15

  Online published: 2022-11-10

Fold

本文引用格式

舒兰, 陈小松 . ER+/HER2-乳腺癌多基因阵列检测应用：ASCO指南解读与瑞金医院临床实践[J]. 外科理论与实践, 2022 , 27(05) : 416 -420 . DOI: 10.16139/j.1007-9610.2022.05.008

参考文献

[1] 陈小松, 沈坤炜. 乳腺癌多基因阵列表达谱检测与个体化治疗[J]. 中华外科杂志, 2017, 55(2):99-103.
[2] Harris LN, Ismaila N, McShane LM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol, 2016, 34(10):1134-1150.
[3] Krop I, Ismaila N, Andre F, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update[J]. J Clin Oncol, 2017, 35(24):2838-2847.
[4] Andre F, Ismaila N, Henry NL, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: ASCO clinical practice guideline update—integration of results from TAILORx[J]. J Clin Oncol, 2019, 37(22):1956-1964.
[5] Andre F, Ismaila N, Allison KH, et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update[J]. J Clin Oncol, 2022, 40(16):1816-1837.
[6] 陈小松, 沈坤炜. 多基因阵列表达谱检测在乳腺癌中的应用[J]. 外科理论与实践, 2019, 24(5):412-416.
[7] Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer[J]. N Engl J Med, 2004, 351(27):2817-2826.
[8] 陈小松, 陈舒婕, 沈坤炜. 乳腺癌的分子分型[J]. 中华肿瘤杂志, 2008, 30(9):641-643.
[9] Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer[J]. N Engl J Med, 2018, 379(2):111-121.
[10] Cardoso F, van′t Veer LJ, Bogaerts J, et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer[J]. N Engl J Med, 2016, 375(8):717-729.
[11] Sapino A, Roepman P, Linn S, et al. MammaPrint mole-cular diagnostics on formalin-fixed, paraffin-embedded tissue[J]. J Mol Diagn, 2014, 16(2):190-197.
[12] Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer[J]. N Engl J Med, 2015, 373(21):2005-2014.
[13] Wu J, Fang Y, Lin L, et al. Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients[J]. Oncotarget, 2017, 8(24):38706-38716.
[14] Yu J, Wu J, Huang O, et al. Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26-30[J]. Oncol Lett, 2020, 20(2):1545-1556.
[15] Yu J, Wu J, Huang O, et al. Distribution and influence of the 21-gene recurrence score on chemotherapy decision-making in special type of breast cancer[J]. Am J Cancer Res, 2021, 11(12):6188-6199.
[16] Sparano JA, Gray RJ, Ravdin PM, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer[J]. N Engl J Med, 2019, 380(25):2395-2405.
[17] Sparano JA, Gray RJ, Makower DF, et al. Clinical outcomes in early breast cancer with a high 21-gene recurrence score of 26 to 100 assigned to adjuvant chemotherapy plus endocrine therapy: a secondary analysis of the TAILORx randomized clinical trial[J]. JAMA Oncol, 2020, 6(3):367-374.
[18] Kalinsky K, Barlow WE, Gralow JR, et al. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer[J]. N Engl J Med, 2021, 385(25):2336-2347.
[19] Tong Y, Wu J, Huang O, et al. 21-Gene recurrence score and adjuvant chemotherapy decision for breast cancer patients with positive lymph nodes[J]. Sci Rep, 2019, 9(1):13123.
[20] Piccart M, van′t Veer LJ, Poncet C, et al. 70-Gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age[J]. Lancet Oncol, 2021, 22(4):476-488.
[21] Tsai M, Lo S, Audeh W, et al. Association of 70-gene signature assay findings with physicians′ treatment gui-dance for patients with early breast cancer classified as intermediate risk by the 21-gene assay[J]. JAMA Oncol, 2018, 4(1):e173470.
Options
文章导航

/

〈 〉